ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ABUS Arbutus Biopharma Corporation

2.73
0.01 (0.37%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Arbutus Biopharma Corporation ABUS NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.01 0.37% 2.73 09:00:00
始値 安値 高値 終値 前日終値
2.73 2.70 2.78 2.73 2.72
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1820:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
2024/4/0421:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
2024/3/0821:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
2024/3/0606:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2921:31EDGAR2Form 8-K - Current report
2024/2/2921:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
2024/2/1521:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
2024/2/1506:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1500:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0609:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0609:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0609:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0609:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0821:31EDGAR2Form 8-K - Current report
2024/1/0821:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
2024/1/0506:09EDGAR2Form 8-K - Current report
2023/11/2122:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2023/11/1006:02EDGAR2Form 8-K - Current report
2023/11/0821:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
2023/11/0806:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0721:31EDGAR2Form 8-K - Current report
2023/11/0721:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
2023/11/0721:16EDGAR2Form 8-K - Current report
2023/11/0721:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
2023/10/2420:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
2023/10/1820:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
2023/10/1121:06EDGAR2Form 8-K - Current report
2023/10/1121:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
2023/9/1206:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2023/9/1205:16EDGAR2Form 8-K - Current report
2023/9/1205:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
2023/9/0720:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
2023/8/0405:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
2023/8/0405:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0320:31EDGAR2Form 8-K - Current report
2023/8/0320:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
2023/7/2020:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
2023/7/1405:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/1405:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/7/1305:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/1305:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/7/1305:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/1305:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/7/1220:31EDGAR2Form 8-K - Current report
2023/7/1220:30GLOBEArbutus Appoints Melissa V. Rewolinski, PhD to its Board of..
2023/7/1105:02EDGAR2Form 8-K - Current report
2023/7/1105:01GLOBEArbutus Appoints Two New Executives
2023/6/2120:30GLOBEArbutus Doses First Patient in Additional Treatment Arm of..
2023/6/2115:01GLOBEArbutus Presents Preliminary AB-729 and Pegylated Interferon..
2023/6/0715:01GLOBEArbutus to Present AB-729 and AB-836 Data at EASL Congress..

最近閲覧した銘柄

Delayed Upgrade Clock